Prelude Capital Management, LLC Syros Pharmaceuticals, Inc. Transaction History

Prelude Capital Management, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$4.08 - $5.66 $57,936 - $80,372	-14,200 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$5.01 - $7.48 $2,004 - $2,992	-400 Reduced 2.74%	14,200 $77,000
Q1 2021 May 17, 2021	BUY	$7.19 - $14.95 $2,876 - $5,980	400 Added 2.82%	14,600 $109,000
Q4 2020 Feb 16, 2021	SELL	$6.66 - $14.66 $1,998 - $4,398	-300 Reduced 2.07%	14,200 $154,000
Q3 2020 Nov 16, 2020	BUY	$8.69 - $14.47 $2,607 - $4,341	300 Added 2.11%	14,500 $128,000
Q2 2020 Aug 14, 2020	BUY	$5.21 - $11.03 $73,982 - $156,626	14,200 New	14,200 $151,000
Q3 2019 Nov 14, 2019	SELL	$7.14 - $11.65 $8,489 - $13,851	-1,189 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$5.5 - $9.75 $6,539 - $11,592	1,189 New	1,189 $11,000
Q3 2018 Nov 14, 2018	SELL	$9.74 - $12.92 $7,305 - $9,690	-750 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$10.16 - $13.65 $7,620 - $10,237	750 New	750 $8,000
Q1 2018 May 15, 2018	SELL	$9.47 - $12.98 $4,640 - $6,360	-490 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$8.45 - $17.48 $2,197 - $4,544	-260 Reduced 34.67%	490 $5,000
Q3 2017 Nov 14, 2017	BUY	$13.52 - $23.75 $10,140 - $17,812	750	750 $11,000

Ticker SYRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,236,200
Market Cap $43.1M
Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.